Drug Profile
Research programme: propranolol sublingual - Kedem
Alternative Names: KDM-1102Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Kedem Pharmaceuticals
- Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Small molecules
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in USA (Sublingual)
- 04 Jan 2012 Preclinical trials in Hypertension in USA (Sublingual)